SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (3120)10/26/2020 11:16:35 PM
From: Felix B  Read Replies (1) | Respond to of 3557
 
Ah I missed that today. Lack of efficacy makes more sense than safety given the MOA. So back to my original question, curious how REGN's cocktail will look in a hospitalized setting? Any idea how their trial compares to REGN? Hopefully the cocktail will be more efficacious than single mAb but perhaps in a hospitalized stage it may be too late?